Formycon terminates Phase III "Lotus" trial for FYB206 biosimilar after FDA confirms therapeutic comparability can be demonstrated through existing melanoma study data and analytical program.
Alvotech reported positive adjusted EBITDA and operating profit for the second consecutive quarter, driven by increased product revenue and improved gross margins.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.